First, there is no correlation between the findings found in the plasma and biopsies of patients with CRC (Zaragoza-Huesca et al., 2022), and more studies are needed to determine the potential of hepsin as a biomarker and therapeutic target in patients with metastasis. Here, HPN is linked to colorectal carcinoma.